| (210) | Number of the EPO application | 16734529 |
| (220) | Filing date of the EPO application | 2016.06.21 |
| (80) | EPO patent specification publication (B) | EPB nr. 37/2022, 2022.09.14 |
| (110) | EPO patent number | 3310760 |
| (21) | Number of the application | e 2018 0411 |
| (71) | Name(s) of applicant(s), code of the country | Arena Pharmaceuticals, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | BLACKBURN Anthony C., US;
CASTRO Ryan O., US;
HADD Mark A., US;
MA You-An, US;
MONTALBAN Antonio Garrido, US;
RUETER Jaimie Karyn, US;
SELVEY Lee Alani, US;
SHAKYA Sagar Raj, US;
CARLOS Marlon, US; |
| (73) | Name(s) of owner(s), code of the country | Arena Pharmaceuticals, Inc., US; |
| (54) | Title of the invention | CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 209/94 (2006.01.01); A61K 31/403 (2006.01.01); A61P 37/00 (2006.01.01); A61P 29/00 (2006.01.01); A61P 35/00 (2006.01.01); A61P 9/00 (2006.01.01); A61P 1/00 (2006.01.01); A61P 7/00 (2006.01.01); A61P 3/00 (2006.01.01); A61P 5/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2018.06.30 |
| (30) | Priority | 201562182841 P, 2015.06.22, US; 201562207531 P, 2015.08.20, US |
| (86) | International application | PCT/US2016/038506, 2016.06.21 |
| (87) | International publication | WO 2016/209809, 2016.12.29 |